Lomaira is intended to help obese and overweight patients lose weight. The drug contains phentermine hydrochloride — an appetite suppressor — in a low dose form, which allows patients to take the drug up to three times a day before meals.
Eligible patients will pay no more than 50 cents per tablet through KVK Tech’s Lomaira Lo-Cost Access Program.
Newtown, Pa.-based KVK Tech plans to launch Lomaira by the end of September.
More articles on supply chain:
Valeant defends drug discount program for two heart drugs
Jimmy Kimmel’s EpiPen joke calls out high drug prices at Emmys
4 things to know about generic price spikes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
